Pyrazole oxadiazole derivatives as s1p1 agonists

A compound of formula (I):

• wherein
• R1 denotes Ar1, Het1, Cyc, A, (C1-C6)alkyl, (C2-C6)alkyl, —(CH2)nAr1, (CH2)nHet1 or (CH2)nHet2;
• R2 is Ar2 of Het1;
• R3 denotes Ar1, Ar2, Het1, Het2, Cyc or A,
• or if R1 is Het1, Cyc, A, —(CH2)nAr1, (CH2)nHet1, (CH2)nHet2, (C2-C6)alkyl, or if R1 denotes Ar1 or R2 is Ar2, Het1 or Het2 wherein Ar1 and Ar2 are mono, di- or trisubstituted by the substituents hereby mentioned, R3 also denotes CH3,
• or if R1 denotes Het1, Cyc, A, (C1-C6)alkyl, (C2-C6)alkyl, (CH2)nAr1, (CH2)nHet1, or (CH2)nHet1, R3 also denotes S—(C1-C6-alkyl);
• A is a branched or linear alkyl having 2 to 12 C-atoms, wherein one or more H-atoms may be replaced by Hal, OR4, CN, CO2R4, CF3, cycloalkyl having 3 to 7 ring carbon atoms, Ar1, Ar2, or N(R4)2 and wherein one or more non-adjacent CH2-groups may be replaced by O, NR4, —CO—, NR4CO2—, —CO2—, —NR4CONR4—, —CH═CH—, —C≡C—, or denotes cycloalkyl or cycloalkylalkylene having 3-7 ring C atoms, or denotes Het1 or Het2;
• Z is a branched or linear alkyl having 2 to 12 C-atoms, wherein one or more H-atoms are replaced by Hal, OR4, CN, CO2R4, CF3, cycloalkyl having 3 to 7 ring carbon atoms, Ar1, Ar2, N(R4)2 and/or wherein one or more CH2-groups are replaced by O, NR4, S, —CO—, NR4CO2—, —NR4CONR4—, —CH═CH—, —C≡C—, or denotes cycloalkyl or cycloalkylalkylene having 3-7 ring C atoms;
• Hal is F, Cl, Br or I;
• Ar1 denotes a monocyclic or bicyclic, unsaturated or aromatic carbocyclic ring having 6 to 14 carbon atoms which may be unsubstituted, monosubstituted, disubstituted or trisubstituted by substitutents selected from A, Hal, —OR4, —SO2R4, —CN, —NO2, —N(R3)2, —CO(NR4)2, (NR4)COR4, —CO2R4, —COR4, —SO2N(R4)2, —SO2alkyl, NR4SO2alkyl, NR4SO2alkyl, or C1-C6 alkyl;
• Ar2 denotes a monocyclic or bicyclic, unsaturated or aromatic carbocyclic ring having 6 to 14 carbon atoms which may be unsubstituted, monosubstituted, disubstituted or trisubstituted by substitutents selected from Z, F, Br, I, —OR4, —(CH2)OR4, —(CH2)N(R4)2, perfluoro-alkoxy, —SO2R4, —CN, —NO2, —N(R4)2, —CO(NR4)2, (NR4)COR4, —CO2R4, —COR4, —SO2N(R4)2, —SO2(C1-C6)alkyl, NR4SO2(C1-C6)alkyl, —(CH2)nHet1, —OHet1, —(CH2)nHet2, or —OHet2, or if R3 is Het1, Het2, Ar1, Ar2 or Cyc, or if R1 is Het1, Cyc, A, (C1-C6)alkyl, (C2-C6)alkyl, —(CH2)nAr1, (CH2)nHet1, or (CH2)nHet1, Ar2 also denotes a monocyclic or bicyclic, unsaturated or aromatic carbocyclic ring having 6 to 14 carbon atoms which may be unsubstituted, monosubstituted, disubstituted or trisubstituted by CF3;
• Het1 denotes a monocyclic saturated, unsaturated or aromatic heterocyclic ring or a bicyclic, saturated, or unsaturated heterocyclic ring having 1 to 4 N and/or O atoms which may be unsubstituted, monosubstituted, disubstituted or trisubstituted by substitutents selected from A, Hal, —(CH2)OR4, perfluoro-alkyl, perfluoro-alkoxy, —SO2(R4)2, CN, NO2, —N(R4)2, —CO(NR4)2, (NR4)COR4, —CO2R4, —COR4, —SO2N(R4)2, —SO2alkyl, NR4SO2alkyl, NR4SO2alkyl, or C1-C6 alkyl;
• Het2 denotes a monocyclic or bicyclic, saturated, unsaturated or aromatic heterocyclic ring having 1 to 4 N, O and/or S atoms which may be unsubstituted, monosubstituted, disubstituted or trisubstituted by substitutents selected from A, F, Br, I, —OR4, —(CH2)OR4, perfluoro-alkyl, perfluoro-alkoxy, —SO2(R4)2, CN, NO2, —N(R4)2, —CO(NR4)2, (NR4)COR4, —CO2R4, —COR4, —SO2N(R4)2, —SO2alkyl, NR4SO2alkyl, NR4SO2alkyl, or C1-C6 alkyl;
• Cyc denotes a saturated or unsaturated carbocyclic ring containing 3 to 7 carbon atoms which may be substituted by Hal, A, (C1-C6)alkyl, —[C(R4)2]n—Ar, —[C(R4)2]n-cycloalkyl, OR4, CF3, OCF3, N(R4)2, NR4CON(R4)2, NO2, CN, —[C(R4)2]n—COOR4, —[C(R4)2]—CON(R4)2, NR4COA, NR4SO2A, COR4, CO2R4, SO2N(R4)2, SOA, and/or SO2A;
• R4 is H, A, Cyc or (C1-C6)alkyl;
• n is 1, 2, 3 or 4;
• and pharmaceutically acceptable solvates, tautomers, salts and stereo-isomers thereof.